Viatris Inc
VTRS: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$57.00 | Rsxw | Chqpkskr |
Viatris Raises Guidance Following Strong Second Quarter
Viatris announced strong second-quarter results across all segments, driven by increased demand for COVID-19-related generic products and steady growth in biosimilars. Management raised full-year revenue guidance to $17.5–17.9 billion, up from $17.2–17.8 billion, and raised adjusted EBITDA guidance to $6.15–6.45 billion, up from $6.0–6.4 billion. The company also paid its first dividend of $0.11 per share this quarter. We maintain our fair value estimate of $25 per share on no-moat Viatris.